Health & Science
FDA authorizes 1st antiviral pill for COVID
Posted on · In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.
Health & Science
The FDA authorizes Moderna and J&J COVID vaccine boosters
Posted on · The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.
Health & Science
The FDA OKs Pfizer-BioNTech Booster For People 65+ And At High Risk For Severe COVID
Posted on · A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.
Health & Science
Experts Advise FDA To Authorize Pfizer COVID Booster For People 65 And Older
Posted on · Advisers to the Food and Drug Administration voted against approval of a booster of the Pfizer-BioNTech COVID-19 vaccine for people 16 years and older. They later supported boosters for older people.
Health & Science
Pfizer-BioNTech’s COVID Vaccine Gets Full Approval From The FDA
Posted on · The approval replaces the emergency use authorizations granted last December and could make it easier for employers, the military and universities to mandate vaccination.
Health & Science
Panel Recommends FDA Authorize Johnson & Johnson Vaccine For Emergency Use
Posted on · The Food and Drug Administration typically follows the advice of its expert advisers. A quick agency decision on the Johnson & Johnson vaccine is expected given the state of the pandemic.
Coronavirus
FDA Panel Recommends COVID-19 Vaccine For Emergency Use
Posted on · In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.
Coronavirus
FDA Analysis Of Pfizer COVID-19 Vaccine Finds It Effective And Safe
Posted on · The Food and Drug Administration finds "no specific safety concerns" that would stand in the way of authorization of the vaccine for emergency use. Effectiveness is 95% after two doses.